Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS

B. Dautzenberg, P. Olliaro, B. Ruf, R. Esposito, M. Opravil, J. F. Hoy, W. Rozenbaum, G. P. Carosi, M. Micoud, M. L'Age, N. Pirotta, D. Sassella

Research output: Contribution to journalComment / DebateOtherpeer-review

7 Citations (Scopus)

Abstract

The aim of this double-blind, randomized, placebo-controlled, 12-week study was to assess the efficacy of rifabutin (450 or 600 mg/d) in the treatment of disseminated nontuberculous mycobacterial infection in patients with AIDS. Companion drugs in both arms of the study were ethambutol, clofazimine, and isoniazid. Because of low accrual, the study was prematurely terminated when a total of 382 patients had been enrolled, of which 200 were eligible (i.e., their specimens were culture-positive for Mycobacterium avium complex [MAC] or Mycobacterium xenopi at baseline) and 102 were evaluable (i.e., they were eligible, were treated for a minimum of 6 weeks, and had at least one culture assessment after baseline). The original protocol called for a total of 220 evaluable patients. At week 12, rifabutin treatment was associated with higher, although nonsignificant, rates of bacteriologic conversion than was the placebo arm, with regard to both the eligible patients (25% vs. 18%) and the evaluable patients (45% vs. 38%). Corresponding median times to culture conversion were 42 vs. 63 days (eligible patients) and 43 vs, 69 days (evaluable patients). No significant difference was observed in clinical improvement, mortality, or toxicity between the two treatment arms. The addition of rifabutin to a triple-drug regimen may contribute to the clearance of disseminated MAC infection in patients with AIDS, without causing additional toxicity.

Original languageEnglish
Pages (from-to)705-708
Number of pages4
JournalClinical Infectious Diseases
Volume22
Issue number4
DOIs
Publication statusPublished - 1 Jan 1996

Cite this

Dautzenberg, B. ; Olliaro, P. ; Ruf, B. ; Esposito, R. ; Opravil, M. ; Hoy, J. F. ; Rozenbaum, W. ; Carosi, G. P. ; Micoud, M. ; L'Age, M. ; Pirotta, N. ; Sassella, D. / Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. In: Clinical Infectious Diseases. 1996 ; Vol. 22, No. 4. pp. 705-708.
@article{1bc0fc7eda0b40af832af5868eb63eec,
title = "Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS",
abstract = "The aim of this double-blind, randomized, placebo-controlled, 12-week study was to assess the efficacy of rifabutin (450 or 600 mg/d) in the treatment of disseminated nontuberculous mycobacterial infection in patients with AIDS. Companion drugs in both arms of the study were ethambutol, clofazimine, and isoniazid. Because of low accrual, the study was prematurely terminated when a total of 382 patients had been enrolled, of which 200 were eligible (i.e., their specimens were culture-positive for Mycobacterium avium complex [MAC] or Mycobacterium xenopi at baseline) and 102 were evaluable (i.e., they were eligible, were treated for a minimum of 6 weeks, and had at least one culture assessment after baseline). The original protocol called for a total of 220 evaluable patients. At week 12, rifabutin treatment was associated with higher, although nonsignificant, rates of bacteriologic conversion than was the placebo arm, with regard to both the eligible patients (25{\%} vs. 18{\%}) and the evaluable patients (45{\%} vs. 38{\%}). Corresponding median times to culture conversion were 42 vs. 63 days (eligible patients) and 43 vs, 69 days (evaluable patients). No significant difference was observed in clinical improvement, mortality, or toxicity between the two treatment arms. The addition of rifabutin to a triple-drug regimen may contribute to the clearance of disseminated MAC infection in patients with AIDS, without causing additional toxicity.",
author = "B. Dautzenberg and P. Olliaro and B. Ruf and R. Esposito and M. Opravil and Hoy, {J. F.} and W. Rozenbaum and Carosi, {G. P.} and M. Micoud and M. L'Age and N. Pirotta and D. Sassella",
year = "1996",
month = "1",
day = "1",
doi = "10.1093/clinids/22.4.705",
language = "English",
volume = "22",
pages = "705--708",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

Dautzenberg, B, Olliaro, P, Ruf, B, Esposito, R, Opravil, M, Hoy, JF, Rozenbaum, W, Carosi, GP, Micoud, M, L'Age, M, Pirotta, N & Sassella, D 1996, 'Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS', Clinical Infectious Diseases, vol. 22, no. 4, pp. 705-708. https://doi.org/10.1093/clinids/22.4.705

Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. / Dautzenberg, B.; Olliaro, P.; Ruf, B.; Esposito, R.; Opravil, M.; Hoy, J. F.; Rozenbaum, W.; Carosi, G. P.; Micoud, M.; L'Age, M.; Pirotta, N.; Sassella, D.

In: Clinical Infectious Diseases, Vol. 22, No. 4, 01.01.1996, p. 705-708.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS

AU - Dautzenberg, B.

AU - Olliaro, P.

AU - Ruf, B.

AU - Esposito, R.

AU - Opravil, M.

AU - Hoy, J. F.

AU - Rozenbaum, W.

AU - Carosi, G. P.

AU - Micoud, M.

AU - L'Age, M.

AU - Pirotta, N.

AU - Sassella, D.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The aim of this double-blind, randomized, placebo-controlled, 12-week study was to assess the efficacy of rifabutin (450 or 600 mg/d) in the treatment of disseminated nontuberculous mycobacterial infection in patients with AIDS. Companion drugs in both arms of the study were ethambutol, clofazimine, and isoniazid. Because of low accrual, the study was prematurely terminated when a total of 382 patients had been enrolled, of which 200 were eligible (i.e., their specimens were culture-positive for Mycobacterium avium complex [MAC] or Mycobacterium xenopi at baseline) and 102 were evaluable (i.e., they were eligible, were treated for a minimum of 6 weeks, and had at least one culture assessment after baseline). The original protocol called for a total of 220 evaluable patients. At week 12, rifabutin treatment was associated with higher, although nonsignificant, rates of bacteriologic conversion than was the placebo arm, with regard to both the eligible patients (25% vs. 18%) and the evaluable patients (45% vs. 38%). Corresponding median times to culture conversion were 42 vs. 63 days (eligible patients) and 43 vs, 69 days (evaluable patients). No significant difference was observed in clinical improvement, mortality, or toxicity between the two treatment arms. The addition of rifabutin to a triple-drug regimen may contribute to the clearance of disseminated MAC infection in patients with AIDS, without causing additional toxicity.

AB - The aim of this double-blind, randomized, placebo-controlled, 12-week study was to assess the efficacy of rifabutin (450 or 600 mg/d) in the treatment of disseminated nontuberculous mycobacterial infection in patients with AIDS. Companion drugs in both arms of the study were ethambutol, clofazimine, and isoniazid. Because of low accrual, the study was prematurely terminated when a total of 382 patients had been enrolled, of which 200 were eligible (i.e., their specimens were culture-positive for Mycobacterium avium complex [MAC] or Mycobacterium xenopi at baseline) and 102 were evaluable (i.e., they were eligible, were treated for a minimum of 6 weeks, and had at least one culture assessment after baseline). The original protocol called for a total of 220 evaluable patients. At week 12, rifabutin treatment was associated with higher, although nonsignificant, rates of bacteriologic conversion than was the placebo arm, with regard to both the eligible patients (25% vs. 18%) and the evaluable patients (45% vs. 38%). Corresponding median times to culture conversion were 42 vs. 63 days (eligible patients) and 43 vs, 69 days (evaluable patients). No significant difference was observed in clinical improvement, mortality, or toxicity between the two treatment arms. The addition of rifabutin to a triple-drug regimen may contribute to the clearance of disseminated MAC infection in patients with AIDS, without causing additional toxicity.

UR - http://www.scopus.com/inward/record.url?scp=9444281435&partnerID=8YFLogxK

U2 - 10.1093/clinids/22.4.705

DO - 10.1093/clinids/22.4.705

M3 - Comment / Debate

VL - 22

SP - 705

EP - 708

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -